Modified Banxia Xiexin Decoction plus chemotherapy shows favorable trends in advanced colorectal cancer
Modified herbal decoction may extend survival time for advanced colorectal cancer patients
This randomized controlled trial in 129 patients with advanced colorectal cancer evaluated modified Banxia Xiexin Decoction (mBXD) granules …
Adding a modified herbal decoction to standard cancer treatment might extend survival time and reduce tumor growth in patients with advanced…
Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival
Pembrolizumab May Cut Liver Cancer Return After Surgery
This is a Phase 3 randomized controlled trial in 959 participants with hepatocellular carcinoma who had a complete radiological response aft…
After liver surgery, pembrolizumab may help keep hepatocellular carcinoma from returning, offering new hope for patients with complete tumor…
Baseline Cytokine Levels Linked to Placebo Response in Cancer Dyspnea Trial
High Inflammation Might Reduce Placebo Effect in Cancer
This exploratory analysis of an RCT in 45 cancer patients with dyspnea found a negative association between baseline cytokine levels and sym…
Scientists found that high inflammation levels may stop the placebo effect from working well.
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
GZR18 showed weight loss in Chinese adults with overweight or obesity in a phase 1b/2a trial
New Drug Cuts Weight by Nearly 20% in Just 35 Weeks
In this randomized, placebo-controlled phase 1b/2a trial, 60 Chinese adults with overweight or obesity received GZR18 or placebo.
This new treatment shows huge promise for helping people reach their weight goals without daily pills.
Memantine reduced PAC burden and new-onset AF in a Phase 2 randomized trial of 241 adults
Common Heart Flutters May Be Linked to Brain Drug
In this Phase 2 randomized, double-blind, placebo-controlled trial of 241 symptomatic adults with frequent PACs (≥1000/24 h), memantine show…
A new study shows a brain medication may calm frequent heart flutters and lower the risk of more serious heart rhythm problems.
Secukinumab 300 mg subcutaneously failed to demonstrate overall response in adults with active Graves orbitopathy versus placebo
Secukinumab showed no benefit for active Graves orbitopathy patients
This randomized, double-blind, placebo-controlled trial evaluated secukinumab versus placebo in 28 adults with active, moderate-to-severe…
Secukinumab treatment for Graves orbitopathy showed no improvement in symptoms or eye measurements compared to placebo treatment.
In an RCT, dutasteride significantly reduced total International Prostate Symptom Score in men with lower urinary tract symptoms over 24 months
Dutasteride Helps Bladder Flow, But Nighttime Relief Takes Years
This randomized controlled trial enrolled 8122 men with lower urinary tract symptoms and compared dutasteride to placebo over a 24.0-month f…
This common prostate medication works well for flow, but full bladder comfort comes slowly and may not be noticeable.
AI endoscopic score shows better agreement with ulcerative colitis remission than Mayo score in RCT
AI endoscopic scoring shows better agreement with ulcerative colitis symptoms in trial
This phase 3 RCT in 387 subjects with ulcerative colitis compared an AI endoscopic cumulative disease score (CDS) to the Mayo endoscopic sco…
An AI scoring system matched ulcerative colitis symptoms better than standard endoscopy, helping doctors align what they see with how patien…
Efgartigimod shows homogeneous efficacy across sexes in AChR-Ab+ generalized myasthenia gravis
New Hope for All Myasthenia Gravis Patients
This post hoc, sex-specific subgroup analysis of the ADAPT Phase 3 RCT evaluated efgartigimod in 86 females and 43 males with AChR-Ab+ gener…
A new treatment for myasthenia gravis works equally well for women and men, offering the same relief from severe muscle weakness regardless …
TTI-0102 Improves Fatigue Scores in MELAS Syndrome Patients During Randomized Phase 2 Trial
New Drug Reduces Fatigue in Rare Mitochondrial Disease
This randomized, single-blind, placebo-controlled Phase 2 trial enrolled 9 patients with MELAS syndrome caused by mtDNA m.3243A>G mutation.
This new medicine could finally give tired patients a sustainable boost in energy without the painful stomach issues that stop people from t…
Phase 2 RCT of IV CN-105 in older adults undergoing noncardiac surgery shows fewer grade 2+ adverse events versus placebo
Could a simple IV drug help older adults avoid confusion after surgery?
This Phase 2 randomized clinical trial enrolled 203 older adults (60 years or older) scheduled for noncardiac or nonintracranial surgery.
A new IV drug given before surgery reduced confusion and side effects in older adults, though more testing is needed to confirm it truly pre…